Major commercial companies have a stable growth in operating performance at the same time, will face a common problem: the monetary tightening of macroeconomic background, the pharmaceutical distribution companies in the financial pressures, the financial costs may continue to climb.
Following the same medicine, Sinopharm shares, after the East China Medicine, August 22, Nanjing Traditional Chinese Medicine has released its 2008 mid-year report. As these business bigwigs the gradual disclosure of semi-annual report, the development of pharmaceutical business in 2008 increasingly clear trend.
General increase profits "In addition to mechanisms of individual enterprises is not straightened out, developed more slowly, the overall results are also in the first half all the more rapidly growing commercial companies, the profitability of these leading companies is also improving." GF Securities analyst Ge Zheng successively issued against a company in the statement and. In addition to the macro aspects of the industry consensus " Medical Reform Accelerated away, thereby promoting the circulation of growth ", major commercial companies have different profit model.
The recently released interim report of the Nanjing Traditional Chinese Medicine 2008: During the reporting period, the company achieved sales of 5.569 billion yuan, up 21.19 percent; profit of 51.223 million yuan, up 10.01%; net profit of 27.9366 million yuan, up 38.08 %. For the Nanjing Traditional Chinese Medicine, while the domestic economic slowdown, inflation and monetary tightening significantly, the macroeconomic situation has tended to be grim, the company integrated logistics and value-added pharmaceutical business as the core building services based on features of Pharmacy Administration Modern integrated supply chain, and comprehensively promote the innovation of traditional business and the business, making operating performance steadily.
The performance of East China Medical's growth is more due to the contribution of faster industrial board. East China Medicine to achieve the first half of revenues 2.967 billion yuan, net profit of 90.3428 million yuan, earnings per share of 0.2081 yuan. East China Chinese pharmaceutical business for the main business, medicine, industry and real estate sales of three parts. "Although the large pharmaceutical business, but lower gross profit margin, the contribution of the company's performance is far better than the pharmaceutical industry." Some analysts evaluate the case. In fact, the East China Chinese medicine this year, 1 to 6 months of business income 2.451 billion yuan, accounting for 82.61% of total operating revenue, but profit contribution of only 145 million, gross margin was 5.91%. The pharmaceutical industry although the income of 479 million yuan, the profit was as high as 395 million yuan, gross margin reached 82.46%, to become the main source of company profits. The U.S. subsidiary of Hangzhou of East China Pharmaceutical Co., Ltd. in the immune suppression Preparation In the field of products and complete, is the largest immune suppression Preparation Manufacturer. However, concern is rising as the overall cost of the pharmaceutical industry and U.S. East China sales growth is gradually slowing down, "reported from view, raw materials, water, electricity and other energy resources, manpower and other cost factors of prices to companies face higher operating and financial pressure on the performance of the company or to a certain extent, performance is subject to cost increases. "analysts said.
Performance are consistent with the more outstanding shares of pharmaceutical and Sinopharm. Same medicine in 2008 mid-year report shows that operating income 3.88 billion yuan, up 20.5%, net profit 76.73 million yuan, up 28.1%, earnings per share 0.27 yuan, in line with expectations. The Sinopharm shares in the first half operating income 2.149 billion yuan, up 26.69%, net profit of 107 million yuan, up 45.72 percent, earnings per share were 0.4481 yuan. Company said the profit increase was mainly attributable to larger, corporate headquarters sales growing faster, better cost control, profit margin stability and growth subsidiaries.
"For pharmaceutical wholesale, we think it is beneficial to the environment of large enterprises, the state of the various policies are tilted to large enterprises. Especially the high-end drug dealers, medical reform in the current environment, the biggest gains." According to industry sources.
Financial pressure
In the major commercial companies have been out of the semi-annual report, you can find under the tightening macro-control policy may lead to the funding crisis by these companies as the biggest challenge. I am a professional editor from Chinese Manufacturers, and my work is to promote a free online trade platform. http://www.chinaqualitycrafts.com/ contain a great deal of information about signature carly , faux suede handbag welcome to visit!
Related Articles -
signature carly, faux suede handbag,
|
